Antibodies News and Research

RSS

New discovery could open door to next generation malaria vaccine

In an unprecedented first, scientists at Seattle Children's Research Institute have developed a genetically attenuated parasite (GAP) that arrests late in the liver stage of human malaria.

16 Jun 2020

UCLA receives nearly $14 million NIH grant to investigate immunotherapy to destroy HIV

UCLA researchers and colleagues have received a $13.65 million grant from the National Institutes of Health to investigate and further develop an immunotherapy known as CAR T, which uses genetically modified stem cells to target and destroy HIV.

16 Jun 2020

Combination of antibodies and internal radiation can help fight cervical cancer

The sugar coating on cancer cells helps them thrive, and a new study indicates patients with cervical cancer who make antibodies to those sugars appear to do better when they also receive internal radiation therapy.

16 Jun 2020

Yale researchers discover the cause for sudden onset of OCD in children

Yale scientists may have found a cause for the sudden onset of obsessive-compulsive disorder (OCD) in some children, they report.

16 Jun 2020

Life saving drug found for COVID-19 patients on ventilators

Results from Oxford University’s RECOVERY trial into existing drugs for the treatment of COVID-19 has found that dexamethasone reduced deaths by a third in ventilated coronavirus patients and by a fifth in coronavirus patients requiring oxygen. This is the first drug of its kind to be demonstrated to have a significant impact on COVID-19 mortality.

16 Jun 2020

SARS-CoV-2 mutation reduces S1 shedding, increases infective potential

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the seventh coronavirus known to infect humans. SARS-CoV-2 emerged in the last month of 2019 in Wuhan, China, sparking off the ongoing COVID-19 pandemic. This virus enters the host cells through receptor binding and membrane fusion between the viral and host cell membrane.

16 Jun 2020

Antibody cocktail is being tested in human COVID-19 trials

Following two studies that screened thousands of human antibodies to SARS-CoV-2 to identify highly potent pairs, in which both antibodies bind the viral target simultaneously, a resultant antibody cocktail is being tested in human trials.

16 Jun 2020

Testing reveals 11 percent of people in Geneva infected with SARS-CoV-2

Now, a team of researchers at Geneva University Hospitals has found that less than 11 percent of the population in Geneva has contracted the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Their research is published in the journal The Lancet.

15 Jun 2020

Human antibodies provide powerful protection against SARS-CoV-2 in animal tests

A team led by Scripps Research has discovered antibodies in the blood of recovered COVID-19 patients that provide powerful protection against SARS-CoV-2, the coronavirus that causes the disease, when tested in animals and human cell cultures.

15 Jun 2020

Trio of studies identifies new human antibodies that target SARS-CoV-2 virus

A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection.

15 Jun 2020

U.S. and European SARS CoV-2 mutation enhances transmission, increases infectivity

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is causing the COVID-19 pandemic across the world has undergone a genetic mutation in the density of functional spikes on the virus, says a new study. This has led the virus to become highly infectious and easily transmissible between humans.

15 Jun 2020

Experimental drug to prevent deadly blood coagulation in patients with COVID-19

The British Heart Foundation is funding a trial for an experimental drug that could prevent the life-threatening blood clots that are seen in the lungs of the patients with COVID-19 or those infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The drug named TRV027 is said to normalize the hormonal imbalance that can be seen in patients developing COVID-19, experts said.

15 Jun 2020

UIC clinical trial to soon test a vaccine for COVID-19

The University of Illinois at Chicago will soon test a vaccine for COVID-19.

15 Jun 2020

Developing a new rapid test for COVID-19

News-Medical speaks to Professor Matt Gibson about his groundbreaking research where his team has developed a new rapid test for COVID-19 detection.

15 Jun 2020

Combination of nelfinar and amodiaquine shows promise for treating COVID-19

Six months into the COVID-19 pandemic, more than 7.4 million people have been infected, and more than 410 000 have died. As yet, there is no treatment or vaccine for the disease.

15 Jun 2020

Researchers are developing new diagnostic tool for rapid detection of coronavirus

Coronavirus diagnostics currently require centralized facilities and collection/distribution of swabs and results are 'next day'.

15 Jun 2020

Tuberculosis and polio vaccines may offer temporary protection against SARS-CoV-2

As the world grapples with the coronavirus disease (COVID-19) pandemic, scientists race to develop an effective vaccine to protect against the deadly SARS-CoV-2 virus. While potential vaccines are still being developed and tested, researchers propose that existing vaccines could give the immune system a temporary boost to ward off infection.

14 Jun 2020

Glycans "lock and load" the SARS-CoV-2 spike protein for infection

A new study by scientists from the University of California San Diego, USA and Maynooth University, Ireland and published on the preprint server bioRxiv* in June 2020 reports preliminary results showing that the spike protein of the SARS-CoV-2, as well as its glycan coat, has “hitherto unseen functional and structural” properties. These may be useful in designing novel therapeutics to target this molecule.

14 Jun 2020

Steroidal drugs subvert SARS-CoV-2 interaction with ACE2 receptors

A new study by Italian researchers and published online on the preprint server bioRxiv* in June 2020 reports the ability of several existing steroidal drugs to reduce the binding of the SARS-CoV-2 to the ACE2 receptor. This could help define newer strategies using viral entry blockers to reduce viral load.

14 Jun 2020

An entire trimeric S-protein of SARS-CoV-2 is necessary for protective immune response

Researchers from Seattle Children's Research Institute and the University of Washington described a high-throughput and rapid technique to quantify circulating levels of functional antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), suggesting that the entire viral spike protein should be used to characterize the immune response. Their paper is currently available on the medRxiv* preprint server.

14 Jun 2020